(ABBV) AbbVie - Ratings and Ratios
Biologics, Immunology, Oncology, Neuroscience, Ophthalmology
ABBV EPS (Earnings per Share)
ABBV Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 27.1% |
| Value at Risk 5%th | 36.5% |
| Relative Tail Risk | -12.50% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.30 |
| Alpha | 32.24 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.349 |
| Beta | 0.423 |
| Beta Downside | 0.675 |
| Drawdowns 3y | |
|---|---|
| Max DD | 20.74% |
| Mean DD | 7.32% |
| Median DD | 6.88% |
Description: ABBV AbbVie September 24, 2025
AbbVie Inc. (NYSE:ABBV) is a research-driven biopharmaceutical firm that develops, manufactures, and commercializes a broad portfolio of medicines across immunology, oncology, neuroscience, eye care, virology, and specialty therapeutics.
Its flagship products include Humira (autoimmune and intestinal diseases), Skyrizi and Rinvoq (psoriasis and inflammatory disorders), Imbruvica and Venclexta (hematologic cancers), Elahere (solid-tumor oncology), and a suite of neuroscience and ophthalmology drugs such as Vraylar, Duopa, Ubrelvy, Qulipta, Ozurdex, and Restasis. The company also markets cosmetic injectables, regenerative-medicine solutions, and gastrointestinal agents like Mavyret, Creon, and Linzess.
In FY 2023 AbbVie generated approximately $58 billion in revenue, with Humira still contributing roughly $2.5 billion despite a 10 % year-over-year decline driven by biosimilar competition. R&D spending was about $5.5 billion, reflecting a continued focus on expanding its oncology pipeline (e.g., Venclexta-based combos) and next-generation immunology candidates. The firm’s operating margin remained above 30 %, a level that is high for the biotech sector.
Key drivers of AbbVie’s outlook include the aging U.S. and global populations that raise demand for chronic-disease biologics, the accelerating rollout of biosimilars that pressure legacy product pricing, and the broader biotech industry’s shift toward gene-editing and cell-therapy platforms, which could reshape competitive dynamics over the next 5-10 years.
For a deeper, data-rich assessment of how these trends may affect AbbVie’s valuation, you may find it worthwhile to explore the analysis on ValueRay.
ABBV Stock Overview
| Market Cap in USD | 410,546m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2013-01-02 |
| Return 12m vs S&P 500 | 25.1% |
| Analyst Rating | 4.0 of 5 |
ABBV Dividends
| Dividend Yield | 2.82% |
| Yield on Cost 5y | 8.11% |
| Yield CAGR 5y | 7.06% |
| Payout Consistency | 100.0% |
| Payout Ratio | 69.4% |
ABBV Growth Ratios
| CAGR 3y | 18.92% |
| CAGR/Max DD Calmar Ratio | 0.91 |
| CAGR/Mean DD Pain Ratio | 2.58 |
| Current Volume | 5420.7k |
| Average Volume | 5246.7k |
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (2.39b TTM) > 0 and > 6% of Revenue (6% = 3.58b TTM) |
| FCFTA 0.15 (>2.0%) and ΔFCFTA 4.47pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -18.19% (prev -27.51%; Δ 9.32pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.16 (>3.0%) and CFO 20.86b > Net Income 2.39b (YES >=105%, WARN >=100%) |
| Net Debt (63.11b) to EBITDA (12.72b) ratio: 4.96 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.72 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.77b) change vs 12m ago 0.0% (target <= -2.0% for YES) |
| Gross Margin 76.21% (prev 67.21%; Δ 9.00pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 43.01% (prev 38.72%; Δ 4.29pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.59 (EBITDA TTM 12.72b / Interest Expense TTM 2.81b) >= 6 (WARN >= 3) |
Altman Z'' -0.78
| (A) -0.08 = (Total Current Assets 28.54b - Total Current Liabilities 39.39b) / Total Assets 133.90b |
| (B) -0.11 = Retained Earnings (Balance) -14.23b / Total Assets 133.90b |
| (C) 0.03 = EBIT TTM 4.47b / Avg Total Assets 138.66b |
| (D) -0.12 = Book Value of Equity -15.79b / Total Liabilities 136.50b |
| Total Rating: -0.78 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 50.63
| 1. Piotroski 4.0pt = -1.0 |
| 2. FCF Yield 4.34% = 2.17 |
| 3. FCF Margin 34.49% = 7.50 |
| 4. Debt/Equity -26.02 = -2.50 |
| 5. Debt/Ebitda 4.96 = -2.50 |
| 6. ROIC - WACC (= -4.83)% = -6.04 |
| 7. RoE 498.8% = 2.50 |
| 8. Rev. Trend 44.44% = 3.33 |
| 9. EPS Trend -56.82% = -2.84 |
What is the price of ABBV shares?
Over the past week, the price has changed by +6.24%, over one month by +2.42%, over three months by +13.30% and over the past year by +44.63%.
Is AbbVie a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ABBV is around 263.69 USD . This means that ABBV is currently undervalued and has a potential upside of +13.48% (Margin of Safety).
Is ABBV a buy, sell or hold?
- Strong Buy: 12
- Buy: 4
- Hold: 12
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ABBV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 243.6 | 4.8% |
| Analysts Target Price | 243.6 | 4.8% |
| ValueRay Target Price | 288.8 | 24.3% |
ABBV Fundamental Data Overview November 15, 2025
P/E Trailing = 175.9773
P/E Forward = 16.6667
P/S = 6.8833
P/B = 50.4573
P/EG = 0.4186
Beta = 0.352
Revenue TTM = 59.64b USD
EBIT TTM = 4.47b USD
EBITDA TTM = 12.72b USD
Long Term Debt = 62.97b USD (from longTermDebt, last quarter)
Short Term Debt = 5.77b USD (from shortTermDebt, last quarter)
Debt = 68.74b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 63.11b USD (from netDebt column, last quarter)
Enterprise Value = 473.62b USD (410.55b + Debt 68.74b - CCE 5.67b)
Interest Coverage Ratio = 1.59 (Ebit TTM 4.47b / Interest Expense TTM 2.81b)
FCF Yield = 4.34% (FCF TTM 20.57b / Enterprise Value 473.62b)
FCF Margin = 34.49% (FCF TTM 20.57b / Revenue TTM 59.64b)
Net Margin = 4.01% (Net Income TTM 2.39b / Revenue TTM 59.64b)
Gross Margin = 76.21% ((Revenue TTM 59.64b - Cost of Revenue TTM 14.19b) / Revenue TTM)
Gross Margin QoQ = 78.51% (prev 84.42%)
Tobins Q-Ratio = 3.54 (Enterprise Value 473.62b / Total Assets 133.90b)
Interest Expense / Debt = 0.97% (Interest Expense 667.0m / Debt 68.74b)
Taxrate = 73.67% (526.0m / 714.0m)
NOPAT = 1.18b (EBIT 4.47b * (1 - 73.67%))
Current Ratio = 0.72 (Total Current Assets 28.54b / Total Current Liabilities 39.39b)
Debt / Equity = -26.02 (negative equity) (Debt 68.74b / totalStockholderEquity, last quarter -2.64b)
Debt / EBITDA = 4.96 (Net Debt 63.11b / EBITDA 12.72b)
Debt / FCF = 3.07 (Net Debt 63.11b / FCF TTM 20.57b)
Total Stockholder Equity = 480.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.79% (Net Income 2.39b / Total Assets 133.90b)
RoE = 498.8% (Net Income TTM 2.39b / Total Stockholder Equity 480.0m)
RoCE = 7.04% (EBIT 4.47b / Capital Employed (Equity 480.0m + L.T.Debt 62.97b))
RoIC = 1.69% (NOPAT 1.18b / Invested Capital 69.54b)
WACC = 6.52% (E(410.55b)/V(479.29b) * Re(7.57%) + D(68.74b)/V(479.29b) * Rd(0.97%) * (1-Tc(0.74)))
Discount Rate = 7.57% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 78.09% ; FCFE base≈18.59b ; Y1≈18.34b ; Y5≈18.95b
Fair Price DCF = 190.1 (DCF Value 336.02b / Shares Outstanding 1.77b; 5y FCF grow -2.17% → 3.0% )
EPS Correlation: -56.82 | EPS CAGR: -21.35% | SUE: -4.0 | # QB: 0
Revenue Correlation: 44.44 | Revenue CAGR: 1.55% | SUE: 0.41 | # QB: 0
Additional Sources for ABBV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle